Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 10:07 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2137–2160 of 3,692 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Non-small Cell Lung Cancers Clear all

Conditions: Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm, Neoplasms by Site, Papillomavirus Infection, Epstein-Barr Virus Infections, Carcinoma, Neoplasms, Vulvar Neoplasms, Vulvar Diseases, Abdominal Neoplasm, NSCLC (Non-small Cell Lung Cancer), Colorectal Cancer
Interventions: STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere); Drug · Combination Product
Lead sponsor: Marengo Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 13
States / cities: Sacramento, California • Celebration, Florida • Miami, Florida + 10 more

Conditions: Non Small Cell Lung Cancer, Lung Cancer
Interventions: ABT-751 and Carboplatin; Drug
Lead sponsor: Konstantin Dragnev; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Advanced Stage Non-small Cell Lung Cancer
Interventions: nivolumab, pilimumab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Lung Cancer, Non-Small Cell
Interventions: HYCAMTIN, oral capsules, Radiation; Drug · Radiation
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 472 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 46
States / cities: Birmingham, Alabama • Glendale, Arizona • Hot Springs, Arkansas + 40 more

Conditions: Non-small Cell Lung Cancer
Interventions: ramucirumab, nab-paclitaxel; Drug
Lead sponsor: Liza Villaruz, MD; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Lung Cancer, Metastatic Cancer
Interventions: microarray analysis, mutation analysis, flow cytometry, immunologic technique; Genetic · Other
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal, Malignant Melanoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Interventions: PF-08046037, sasanlimab; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 14
States / cities: Denver, Colorado • New Haven, Connecticut • Trumbull, Connecticut + 3 more

Conditions: Non-Small Cell Carcinoma of Lung, TNM Stage 4
Interventions: Arm A, Arm B; Drug
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions: Durvalumab, Selumetinib, Tremelimumab; Biological · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Non-Small Cell Lung Cancer
Interventions: Nivolumab, Carboplatin, Paclitaxel, Ipilimumab; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 4
States / cities: Baltimore, Maryland • New York, New York • Edmonds, Washington

Conditions: Advanced Solid Tumors
Interventions: INCB099280, adagrasib; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 5
States / cities: Los Angeles, California • Greeley, Colorado • Detroit, Michigan + 2 more

Conditions: Lung Cancer
Interventions: computed tomography, fludeoxyglucose F 18, hypofractionated radiation therapy, stereotactic radiosurgery; Procedure · Radiation
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Lung Cancer, Precancerous Condition
Interventions: iloprost, placebo; Drug · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 85 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 6
States / cities: Aurora, Colorado • Denver, Colorado • Baltimore, Maryland + 3 more

Conditions: Non-small Cell Lung Cancer
Interventions: ISIS EIF4E Rx, Paclitaxel, Carboplatin; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 10
States / cities: Birmingham, Alabama • Fayetteville, Arkansas • Hot Springs, Arkansas + 6 more

Conditions: Non Small Cell Lung Cancer, Cancer
Interventions: Venetoclax, Pembrolizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 39
States / cities: Birmingham, Alabama • Tucson, Arizona • Santa Rosa, California + 31 more

Conditions: Non-small Cell Lung Cancer
Interventions: 45 Gray (Gy) regimen; Radiation
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 6
States / cities: Greenwich, Connecticut • Guilford, Connecticut • Hamden, Connecticut + 3 more

Conditions: End of Life, Cancer
Interventions: Receive technology-based supportive cancer care, Receive redesigned team-based supportive cancer care; Other · Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 2,996 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 17
States / cities: Birmingham, Alabama • Mobile, Alabama • Duarte, California + 11 more

Conditions: Peripheral T Cell Lymphoma, Diffuse Large B-cell Lymphoma, Classical Hodgkin Lymphoma, Head and Neck Squamous Cell Carcinoma, Melanoma, Non-Small Cell Lung Cancer
Interventions: PF-08046032, Sasanlimab; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: San Antonio, Texas • Seattle, Washington

Conditions: Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Interventions: Cisplatin, Docetaxel, Laboratory Biomarker Analysis, Nintedanib; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Early Stage Non-Small Cell Lung Cancer
Interventions: Vancomycin, Precision hypofractionated radiation; Drug · Radiation
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer, Cognitive/Functional Effects, Lung Cancer, Metastatic Cancer, Prostate Cancer
Interventions: radiation therapy, stereotactic radiosurgery; Radiation
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2019
U.S. locations: 60
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Modesto, California + 50 more

Conditions: Stage IV Melanoma, Advanced Lung Cancer, Stage IV Non-Small Cell Lung Cancer, Unresectable Non-Small Cell Lung Carcinoma, Unresectable Stage III Non-Small Cell Lung Cancer, Small Cell Lung Cancer Extensive Stage, Stage IV Merkel Cell Carcinoma, Stage IV Cutaneous Squamous Cell Carcinoma, Stage IV Basal Cell Carcinoma, Stage IV Breast Cancer, Stage IV Colorectal Cancer, Stage IV Gastric Cancer, Stage IV Esophageal Cancer, Stage IV Hepatocellular Cancer, Stage IV Renal Cell Carcinoma, Stage IV Bladder Cancer, Stage IV Head and Neck Squamous Cell Carcinoma, Stage IV Cervical Cancer, Stage IV Endometrial Cancer, Stage IV Mesothelioma, Immunotherapy, Immune Checkpoint Inhibitors
Interventions: Educational Video and QPL List, Usual Care; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 199 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Colorectal Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer
Interventions: questionnaire administration, quality-of-life assessment; Other · Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 605 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Locally-Advanced Non-Small Cell Lung Cancer
Interventions: NBTXR3; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

Pharmacokinetic & Pharmacodynamic Study of ABT-751 With Carboplatin in Patients With Advanced Lung Cancer

Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs

Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer

Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Identifying Early Lung Cancer Cells in Malignant Pleural Effusion Samples From Patients With Primary Lung Cancer

A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies

Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC

Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer

Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC

A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation

Stereotactic Radiosurgery in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer

Iloprost in Preventing Lung Cancer in Patients at High Risk for This Disease

Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel

A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression

Dose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung Cancer

Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer

A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers

Cisplatin, Docetaxel, and Nintedanib Before Surgery in Treating Patients With Previously Untreated Stage IB-IIIA Non-small Cell Lung Cancer

Safety Trial of Antimicrobial Therapy and Precision Radiation Therapy in Patients With Oligoprogressive Non-small Cell Lung Cancer

Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases

Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer

Disease Management Program or Usual Care in Patients With Stage III or Stage IV Lung Cancer, Pancreatic Cancer, Ovarian Cancer, or Colorectal Cancer, and Their Caregivers

NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung Cancer